Panno thoughts

Author’s reply »I think we need to make one thing clear and that is that efficacy for TT-034 only applies to TT-034. In terms of the other pipeline programs, the TT-034 trial can be seen as a "proof of concept" and this will be useful in selling other pipeline programs but it in no way guarantees their success; especially when different vectors are being used. Having said that, if TT-034 is successful, that should stir up some interest in the other pipeline programs.


What we also have to consider is that (thus far) no big pharma has shown any interest is ddRNAi as a tecchnology. This could mean that any interest in our pipeline will be program specific, that is, if a particular target disease falls within the profile of the interested party. The real key here is for the Benitec to be able to structure one or more deals in the pre-clinial stage which have milestones that cover big pharmas risk. To date, Benitec has been particularly inept at doing so when compared to its peers.


So, success for TT-034 will only have a real impact, IMO, if Benitec can leverage this success and strike a deal. New money will then be able to be applied to the other programs and the pipeline will accelerate. If Benitec does not manage to do a deal, the pps will jump on the success of TT-034 and then fall away - again.